Blood Purification in Septic Children

Sponsor
Children's Hospital of Fudan University
Study ID
NCT05595239
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Blood Purification
  • Sepsis

Eligibility Criteria

Sex
ALL
Age
29 Days - 18 Years
Healthy Volunteers
Not accepted

Interventions

  • blood purification(CVVH) — DEVICE
    After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode, 24 hours per day, for 3 consecutive days
  • blood purification(TPE+CVVH) — DEVICE
    After the sepsis patients were enrolled, they were treated with blood purification in TPE mode 2 hours at first and then in CVVH mode 22 hours in the first two days, and then in CVVH mode 24 hours
  • blood purification(HP+CVVH) — DEVICE
    After the sepsis patients were enrolled, they were treated with blood purification in HP mode 2 hours at first and then in CVVH mode 22 hours in the first two days, and then in CVVH mode 24 hours

Study Details

In septic shock, dysregulated host responses to pathogens lead to cytokine storms that damage host tissues and organs, further contributing to the development of organ dysfunction and increased mortality. For sepsis, blood purification can remove inflammatory factors in sepsis by filtration or adsorption, so as to achieve the purpose of reducing inflammatory mediators in the body. However, there are few prospective randomized controlled studies in children. Therefore, this study intends to compare the efficacy and prognosis of different blood purifications on children with sepsis through randomized controlled studies, so as to provide a corresponding basis for the treatment of children with sepsis blood purification.

Key Dates

First listed
Oct 26, 2022
Start date
Jul 1, 2026
Status verified
Feb 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: standard treatment+CVVH
  • Experimental: standard treatment+TPE+CVVH
  • Experimental: standard treatment+HP+CVVH

Primary Outcome Measure

cytokine change [ Time Frame: from enrollment to the 3th days ]

Related Studies